Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostatic Neoplasms × lanreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neuroendocrine Tumors 11 Carcinoid Tumor 5 Acromegaly 3 Serotonin Syndrome 2 Pituitary Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Prostatic Neoplasms 1 Pheochromocytoma 1 Peritoneal Neoplasms 1 Paraganglioma 1 Pancreatic Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Neoplasms 1 Neoplasm Metastasis 1 Intestinal Obstruction 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Carcinoid Heart Disease 1 Adenoma, Islet Cell 1

Interventions

Docetaxel 244 Prednisone 196 enzalutamide 149 Leuprolide 146 Radiotherapy 139 Abiraterone Acetate 126 Magnetic Resonance Spectroscopy 123 bicalutamide 111 Goserelin 111 Androgen Antagonists 92 Radiosurgery 89 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 88 apalutamide 65 gallium 68 PSMA-11 60 abiraterone 59 Specimen Handling 59 Radiation 50 Gonadotropin-Releasing Hormone 49 darolutamide 47 cabazitaxel 43 Triptorelin Pamoate 43 Brachytherapy 43 pembrolizumab 42 Zoledronic Acid 40 Carboplatin 40 luprolide acetate gel depot 39 Estramustine 39 Biopsy 39 Standard of Care 38 Pluvicto 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01313273 2019-11-22

POSEIDON

Ipsen

Phase 3 Terminated

3 enrolled 4 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡